TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03630315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-TKI
Description: OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Standard of care therapy used to block vascular endothelial growth factor
Study: NCT02061488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: open-loop night
Description: During the open-loop night the patient is using his insulin pump as usual
Study: NCT01134081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival Graft
Description: Harvested tissue from palate
Study: NCT02909140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical phenylephrine 2.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical phenylephrine 2.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical cyclopentolate 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical cyclopentolate 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral Lidocaine 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral Lidocaine 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral Lidocaine 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral 0.2- 0.3ml of epinephrine 1:10,000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intracameral 0.2- 0.3ml of epinephrine 1:10,000
Study: NCT00417209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotaxel (XRP9881)
Description: administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: administered as IV infusion from Day 1 to Day 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: administered orally from Day 1 to Day 14 q3w
Study: NCT01989728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychiatric examination and feedback

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychiatric examination and feedback
Study: NCT02217865

Intervention type: BEHAVIORAL
Intervention: Interviews - Colorectal Cancer Participants
Description: Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.

Intervention type: BEHAVIORAL
Intervention: Interviews - Colorectal Cancer Participants
Description: Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire completion asking general health and demographic questions.
Study: NCT02061488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed-loop night
Description: During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
Study: NCT01954446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M
Description: Conventional measuring of BP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M
Description: Conventional measuring of BP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ContiPressTM
Description: New way of measuring BP - ContiPressTM~Investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ContiPressTM
Description: New way of measuring BP - ContiPressTM~Investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobil-O-Graph
Description: 2 different devices for oscillometric measurement of BP
Study: NCT02217865

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.

Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.

Intervention type: BEHAVIORAL
Intervention: Interviews - Caregivers of Colorectal Cancer Participants
Description: Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
Study: NCT00842842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tack fixation of mesh
Description: tack fixation of mesh

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glue fixation of mesh
Description: glue fixation of mesh
Study: NCT00678366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of 4% oxygen
Description: addition of 4% oxygen to the carbon dioxide pneumoperitoneum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxde
Description: classic pneumoperitoneum with 100 % carbon dioxide
Study: NCT03744416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling based on Epstein's active decision making
Description: Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth.
Study: NCT03765632

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)
Description: Autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) are infused intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan is used for non-myeloablative conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Ada
Description: Peg-Ada Enzyme Replacement Therapy (ERT) is discontinued at Day +30 (-3/+15 days) after successful engraftment
Study: NCT02068482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
Study: NCT00418470

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regular dilution of antibiotic in NS
Description: IV administration of ceftazidime tid diluted in regular NS volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: higher dilution of antibiotic in NS
Description: IV administration of ceftazidime tid diluted in larger NS volume
Study: NCT00633282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style intervention
Description: calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style intervention
Description: calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style intervention
Description: calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: berberine
Description: berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
Study: NCT03196999

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Attention Bias Training
Description: This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Attention Training Condition
Description: This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Personalized Attention Bias Training
Description: This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
Study: NCT02433665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mydose
Description: 400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
Study: NCT02030184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhenium Re 188-P2045
Description: Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
Study: NCT01259869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: 1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
Study: NCT03304600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active stimulation
Description: Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Patients will receive a Sham stimulation during 30 mn
Study: NCT04318665

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Perfusion
Description: Severe Traumatic Brain Injury patients will be undergoing CT perfusion test
Study: NCT04418726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified Monitoring
Description: Apart from clinical assessment, use non-invasive devices to check for the haemodynamic consequences of stenosis by measuring Qa, using either indicator dilution techniques or duplex ultrasound every month.
Study: NCT01298570

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib (BAY 73-4506)
Description: Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
Study: NCT03500484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
Study: NCT01243554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training at the hospital
Study: NCT02498548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trained SCI Knee or Trained SCI Hip
Description: Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control or hip control, members of this group will be trained at slow to moderate gait speeds.
Study: NCT00925314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CB-10-01 (Transgenic Lymphocyte Immunization)
Description: 1 Primary Infusion and 2 Booster Infusions
Study: NCT03172780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium gel 1%
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
Description: Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Vehicle Gel 4 gm, 4 times a day for 4 weeks
Study: NCT01969357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets(n=4),once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg SP2086
Description: Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg SP2086
Description: Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg SP2086
Description: Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg Sitagliptin
Description: Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
Study: NCT03238066

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: HDR/PDR brachytherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Interstitial hyperthermia
Study: NCT04217720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-301
Description: SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
Study: NCT04910490

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new/additional patients will be enrolled within this project.

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new/additional patients will be enrolled within this project.
Study: NCT04347291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMS 2.0
Description: FAMS components include monthly phone coaching following a semi-structured protocol plus daily automated text message support to the patient participant and less frequent automated text messages to their support person, if enrolled.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Print Materials
Description: Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Print Materials
Description: Quality print materials about diabetes management provided upon enrollment and in quarterly study newsletters.
Study: NCT01632709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: one injection of 10ml of .25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: one injection of 10ml of .25%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry needling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry needling
Study: NCT03314025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride 0.4 MG
Description: Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Foley catheter
Description: Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
Study: NCT04611698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha sound processor BA400
Description: Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baha sound processor BA400
Description: Baha sound processor BA400 is a cochlear implant designed specifically for soft tissue preservation.
Study: NCT03735602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perceptual training
Description: orientation discrimination task
Study: NCT00220701

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lexapro (escitalopram)
Description: antidepressant drug selective serotonin reuptake inhibitor (SSRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro (escitalopram)
Description: antidepressant drug selective serotonin reuptake inhibitor (SSRI)
Study: NCT03841032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone, BAY1183345
Description: Lotion, for 4 weeks
Study: NCT00706745

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oil rich in cis9, trans11 conjugated linoleic acid
Description: An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oil rich in cis9, trans11 conjugated linoleic acid
Description: An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: identical placebo capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo capsules.
Study: NCT04360031

Intervention type: DRUG
Intervention: Tacrolimus
Description: Tacrolimus and Mycophenolate Mofetil are given in accordance with patient's current regimen
Study: NCT05014308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric Alveolar Decortication, fibrotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric Alveolar Decortication, fibrotomy
Study: NCT00802451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine